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Abstract 
Objectives: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of 
this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in patients under mono 
or dual therapy. 
Methods: This was a prospective multicenter cohort study of patients using DRV/r under mono or dual therapy plus 
lamivudine who changed to DRV/c maintaining the previous regimen. All patients had a controlled HIV viral load 
(<50 copies/ml) when switched and were examined every 12 weeks. The primary end-point was the percentage of 
participants without virological failure (VF) at week 48 in the intent-to-treat analysis. The CD4 cell count and 
concentrations of cholesterol, triglyceride, and creatinine were measured from baseline to week 48. 
Results: A total of 162 patients were included: 68.5% were men, and their mean age was 46 ± 12 years. Seventy 
(43.2%) patients were treated with DRV/r monotherapy, and 92 (56.8%) were treated with DRV/r plus lamivudine. 
The efficacy at week 48 was 95.1% (95% CI: 90.6%–97.5%) in the intent-to-treat analysis and 98.7% (95.5–99.6%) 
in the on-treatment analysis. Two VFs were documented but without development of resistance mutations. No 
significant changes were found in the lipid profile. Creatinine concentration increased significantly by 0.07 mg/dl 
(0.04–0.10, P < 0.001). 
Conclusions: Switching from DRV/r to DRV/c in patients under mono or dual therapy is safe and effective. 










The current standard recommendation for HIV treatment is three antiretroviral drugs. The extended 
use of some NRTIs is associated with adverse events, such as renal and cardiovascular toxicity, and mono 




Boosted PI monotherapy with lopinavir or darunavir (DRV) has proven efficacy in clinical trials and 
reallife cohort studies when applied in selected patients.
3,4
 In the MONET Study, switching to 
DRV/ritonavir (DRV/r) monotherapy was as effective in controlling HIV replication as DRV/r plus two 
NRTIs after 144 weeks (if switches were not considered to be failures).
5
 Dual therapy with DRV/r plus 





Cobicistat, a cytochrome P450-3A inhibitor, has been developed as a booster for other antiretroviral 
agents and is used as a co-formulation with DRV, atazanavir and elvitegravir. Cobicistat is a more 
specific inhibitor than ritonavir, and there are some differences in the drug-interaction profiles. The 
pharmacokinetics of DRV 800 mg QD administered with 150 mg of cobicistat is bioequivalent to that 
observed with ritonavir in terms of the AUC and Cmax, even though the Cmin is significantly lower with 




There are few data on the use of DRV/cobicistat (DRV/c) in mono or dual therapies. The aim of this 
study was to evaluate the efficacy of switching from a DRV/r-based mono or dual therapy (plus 3TC) to a 
DRV/c-based while retaining the previous regimen. 
Methods 
This was an observational, prospective cohort study of HIV-infected patients treated with a DRV/r-
containing mono or dual therapy (plus 3TC) who switched to DRV/c while maintaining the same 
regimen. Three clinics in Spain participated in the study; in these clinics, around 2,100 HIV-infected 
patients are on ART. The research protocol was reviewed and approved by the Regional Ethics 
Committee (register code 2014/500). All clinical data were anonymized and de-identified prior to be 
analysis, the identification numbers of the patients were blinded. 
 
All patients included were aged >18 years and had an HIV RNA <50 copies/ml at the time of the 
switch. Patients were under mono or dual therapy as usual clinical practice and have to be taking the same 
treatment at least 3 months before switching to DRV/c. 
 
The epidemiological and clinical data, treatment exposure and reasons for mono or dual therapy were 
recorded. Patients with detectable HCV-RNA at baseline were considered HCV-coinfected. Patients were 
followed up every 12 weeks until they either changed or discontinued the treatment, or to the last 
observation for patients who did not interrupt their treatment. During the follow-up, virological and 
immunological data were collected. The estimated glomerular filtration rate (eGFR) was calculated using 
the CKD Epidemiology Collaboration (CKD-EPI) formula. For patients who interrupted the treatment, 
the date and reason for discontinuation were also registered. Adverse events were categorized via the 




Virological failure (VF) was defined as two consecutive HIV-RNA measurements >50 copies/ml or 
one detectable HIV RNA measurement made at the last visit. A resistance study was performed in 
patients with VF. 
 
Adherence to ART was measured by self-report and pill count (calculated by dividing the number of 
doses left to the patient by the number of doses dispensed). 
  
The primary end-point was the percentage of participants without VF at week 48 analyzed with an 
intent-to-treat approach (incomplete/missing data = failure). The secondary end-points were the efficacy 
in an on-treatment analysis. The changes in CD4 cell count and fasting lipid and creatinine concentrations 
were analyzed. 
 
Continuous variables are reported as mean ± standard deviation (SD) or median (range), as indicated. 
For categorical variables, absolute numbers and percentages were computed. Changes in continuous 
measures from baseline to week 48 were analyzed using the Wilcoxon signed-rank test. The primary end-
point is expressed using the two-sided 95% CI. 
Results 
A total of 162 patients whose medication was switched from mono or dual therapy (plus 3TC) 
containing DRV/r (all 800/100 mg QD) to one containing DRV/c were included, and followed up to week 
48. During the inclusion period, 171 patients changed the therapy, of which 162 patients (94.7%) 
accepted to participate. The main characteristics of the study population are shown in Table 1. 
Table 1 Main characteristics of the study population and laboratory parameters during the follow-up 
 Basala Week 24 Week 48 ∆basal-w48
b P value 
      
Age (years)  46 ± 12     
Sex, male (%)  111 (68.5)     
Transmission route      
IDU (%)  36 (22.2)     
Sexual (%)  126 (77.8)     
CD4 nadir (cells/μl)  191 ± 86     
CDC C Category (%)  39 (24.1)     
Length of HIV infection (years)  12 (6–17)     
HCV coinfection (%)  32 (20.4)     
Time on ART (years)  9.9 ± 4.0     
Time on LDR (years)  2.3 ± 1.1     
Treatment      
DRV/c monotherapy (%)  70 (43.2)     
DRV/c + 3TC (%)  92 (56.8)     
Adherence >90% (%)  152 (93.8) 147 (94.3) 145 (92.4) – – 
CD4 (cells/μl)  688 ± 301 640 ± 294 702 ± 304 +14 (−60, +88) 0.510 
Total cholesterol (mg/dl)  190 ± 32 187 ± 25 188 ± 32 −4 (−11, +3) 0.212 
LDL-cholesterol (mg/dl)  128 ± 22 124 ± 20 125 ± 28 −2 (−7, +4) 0.416 
HDL-cholesterol (mg/dl)  44 ± 14 43 ± 13 42 ± 12 −3 (−5, +1) 0.073 
Triglycerides (mg/dl)  172 ± 96 165 ± 75 162 ± 90 −5 (−26, +8) 0.096 
Creatinine (mg/dl)  1.03 ± 0.10 1.09 ± 0.10 1.08 ± 0.14 +0.07 (0.04, 0.10) <0.001 
eGFR (ml/min/1.73 m2)  87.4 ± 10.2 83.1 ± 9.7 83.8 ± 11.0 −4.0 (−6.3, −0.9) <0.001 
      
 
IDU, intravenous drug use; ART, antiretroviral treatment; LDR, less drugs regimen; DRV/c, darunavir/cobicistat; 3TC, lamivudine; 
eGFR, estimated glomerular filtration rate (CKD-EPI). 
a Last determination before switching. 
b Change from basal to week 48, expressed with the 95% CI. 
The reasons for mono or dual therapy use were: NRTI toxicity (44.4%), simplification strategy 
(33.9%), patient’s wishes (11.7%), and other reasons (10.0%). 
 
The efficacy values at week 48 were 95.1% (95% CI: 90.6–97.5%) in the intent-to-treat analysis and 
98.7% (95.5%–99.6%) in the on-treatment analysis. Figure 1 shows the percentages of patients without 





Figure 1 Percentage of patients with HIV viral load <50 copies/ml during treatment with DRV/r (basal) and at various times after 
switching to DRV/c. The intent-to-treat (ITT) and on-treatment (OT) analysis are presented; number inside the bars indicate the % 
of patients without viral failure (top numbers) and the number of patients without viral failure (numerators) of the total analyzed 
(denominators); error bars indicate 95% CIs. 
Eight patients discontinued the DRV/c-based mono or dual therapy. Two were considered to have VF 
and the other six discontinued for other reasons: three patients returned to DRV/r in the same mono or 
dual therapy because of gastrointestinal disturbances before week 12; one patient developed peripheral 
neuropathy (although the investigator did not associate this with DRV/c, the treatment was changed); one 
patient developed non-Hodgkin lymphoma and switched to another regimen to avoid drug interactions; 
and one patients was lost to follow-up in week 36 visit. No other clinical or laboratory severe adverse 
events (grade 3–4) were reported. Serum creatinine concentration increased significantly from baseline to 
week 12 after switching and stabilized later, and the lipid profile did not change significantly (Table 1). 
Eighteen patients had basal eGFR <60 ml/min/1.73 m2 (mean 50 ± 6 ml/min/1.73 m
2
); the increase in 
serum creatinine in patients with moderate renal dysfunction was similar to that observed in those with a 
rate >60 ml/min/1.73 m
2
 (6.0% vs. 5.7%, respectively). 
 
In one of the two patients with VF, the HIV-RNA was 10,600 copies/ml in week 24; this patient 
acknowledged treatment withdrawal, without new resistance to PI in the test, and treatment with DRV/c 
plus two NRTIs was restarted. The other patient was on DRV/c monotherapy and had an HIV-RNA load 
of 320 copies/ml in week 12, which remained detectable 10 days later (198 copies/ml). Subsequently two 
NRTIs were introduced, and the next viral load was undetectable, but it was not possible to perform a 
resistance study; this patient’s adherence during the monotherapy regimen was 70%–80%. 
Discussion 
Our findings suggest that switching from DRV/r to DRV/c in a mono or dual therapy plus 3TC was 
safe and effective after up to 48 weeks after change. To our knowledge, this is the first study to evaluate 
this switching strategy in mono and dual therapy receiving patients. The high efficacy obtained is in 
concordance with data of other study with patients under monotherapy carried in Spain, where only the 
5.12% of patients had any viral load >200 copies/ml after a median follow-up of 7.93 months.
9
 Despite it, 
due to the higher rates of virologic failure, PI monotherapy is not recommended as a simplification 
strategy nowadays. 
 
We found no significant changes in the lipid profile during the follow-up. Previous studies have 
reported similar lipid profiles for patients treated with DRV/r versus DRV/c, although recent data show 
an improvement in triglycerides of patients with basal hypertriglyceridemia that change from ritonavir to 
cobicistat.
10 
Cobicistat, in vitro, promotes less insulin resistance and lipid accumulation than ritonavir, 
offering a benefit even not clinically evident.
11,12
  
Creatinine concentration increased slightly in our patients (0.07 mg/dl) during the first weeks after 
switching and plateaued during the following weeks, with a median descent of eGFR of 4.0 ml/min/1.73 
m
2
, pattern that is consistent with the inhibitory effects of cobicistat on renal tubular creatinine secretion, 
which is not an indicator of renal dysfunction.
11
 Other studies have reported increases in creatinine 
concentration when cobicistat is used with DRV, atazanavir or elvitegravir, and have reported that this 
increase is of a similar magnitude for all drugs.
13–15
 We found similar tolerability, effectiveness and 
effects on renal function in patients with moderate renal dysfunction compared with those having a 
normal eGFR. 
 
In the pharmacokinetic study in healthy volunteers, published by Kakuda et al., the AUC for DRV 800 
mg once daily boosted with cobicistat was bioequivalent to that with ritonavir, but the mean DRV Cmin 
(1,330 ng/ml) and mean pre-dose plasma concentration (C0 = 2,400 ng/ml) are 26%–35% lower when 
boosted with cobicistat.
7
 When DRV/c is administered with a standard meal, the DRV exposure is 
increased by 30%.
13
 The ARTEMIS trial evaluated DRV/r plus two NRTIs in treatment-naïve patients. In 
the DRV pharmacokinetic study of the ARTEMIS, in week 4, the mean AUC (69,359 ng h/ml), Cmin 
(1,189 ng/ml), and C0 (1,826 ng/ml) were lower than obtained when DRV is boosted with cobicistat, but 
the effectiveness was not compromised.7,15 High intra- and interpatient variability have been reported for 
DRV level.
16,17
 There is no evidence of a relationship between the DRV Cmin and C0 and the virological 
response, probably because these concentrations are much higher than the half-maximum effective 





Adherence is crucial in patients treated with a mono or dual therapy. Our study had only two patients 
with VF, one instance of which was secondary to voluntary treatment discontinuation, and this patient 
was probably not a good candidate for mono or dual therapy. The other VF involved low-level viremia in 
a patient with adherence <90%. When treating patients with a DRV/c-containing mono or dual therapy, 
adherence, interactions and administration with meals must be considered. 
 
Our study has some limitations. First, it was a non-comparative design, even though a randomized 
clinical trial would have been the ideal option, it was not possible to carry it out; however, this lack of a 
DRV/r arm can penalize the switching strategy because all patients started with an undetectable viral 
load, besides that the real-life data are also very relevant. Second, the sample size did not allow us to 
detect uncommon adverse events, but previous studies have determined the safety profile of DRV/c.
11
 
Third, we did not include pharmacokinetic data, which would have provided more complete clinical 
information. 
 
In conclusion, switching from DRV/r to DRV/c in patients under mono or dual therapy was shown to 
be safe and effective. These data support this switching strategy in most of patients taking a DRV/r 
containing regimen, with the exception of those who do not tolerate cobicistat and those who have some 
problem of drug interactions, as well as in pregnancy, where neither the cobicistat nor the mono or dual 
therapies are indicated. 
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